NASDAQ:TBPH

Theravance Biopharma Q2 2026 Earnings Results & Report

Theravance Biopharma logo
$17.03 0.00 (0.00%)
As of 11/6/2026

Theravance Biopharma missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.11 versus the $0.0725 consensus estimate, while revenue of $20.73 million fell short of the $22.49 million estimate by $1.76 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

Theravance Biopharma EPS Results

Actual EPS
-$0.11
Consensus EPS
$0.0725
Beat/Miss
Missed by -$0.1825
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Theravance Biopharma Revenue Results

Actual Revenue
$20.73 million
Expected Revenue
$22.49 million
Beat/Miss
Missed by -$1.76 million
YoY Revenue Growth
N/A

Theravance Biopharma Q2 2026 Earnings FAQ

Theravance Biopharma (NASDAQ:TBPH) reported earnings of -$0.11 per share for Q2 2026, missing the consensus estimate of $0.0725. The report was announced on Monday, August 10, 2026.

Theravance Biopharma reported revenue of $20.73 million for Q2 2026, against a consensus estimate of $22.49 million.

Theravance Biopharma Earnings Headlines

Theravance Biopharma (TBPH) Set to Release Earnings on Tuesday
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
See More Theravance Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email.

About Theravance Biopharma

Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for the maintenance of chronic obstructive pulmonary disease (COPD) in adults. In the United States, the product is commercialized through a collaboration with Viatris.

The company was established as an independent business following its separation from Theravance, Inc. in 2014. Its research and development work has included therapies for respiratory and other serious conditions.

Theravance Biopharma is led by Chief Executive Officer Rick E. Winningham.

View Theravance Biopharma Profile